Last reviewed · How we verify
6MW3211
6MW3211 is a monoclonal antibody targeting PD-1.
6MW3211 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | 6MW3211 |
|---|---|
| Also known as | 6MW3211injection, 6MW3211 injection |
| Sponsor | Mabwell (Shanghai) Bioscience Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells, and thus enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS (PHASE1, PHASE2)
- A Clinical Study of 6MW3211 in Patients With Renal Cancer (PHASE2)
- A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma (PHASE2)
- A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer (PHASE2)
- A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6MW3211 CI brief — competitive landscape report
- 6MW3211 updates RSS · CI watch RSS
- Mabwell (Shanghai) Bioscience Co., Ltd. portfolio CI